REPOMIA is recombinant human erythropoietin alpha (rHuEPO). Erythropoietin is a glycoprotein, which stimulates red blood cell (Erythropoiesis) production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Erythropoietin stimulates erythropoiesis in anemic patients with chronic renal failure in whom the endogenous production of erythropoietin is impaired.
REPOMIA
COMPOSITION:
Pre-filled syringes of Recombinant Human Erythropoietin Alpha Inj. (4000 IU/mL, 5000 IU/mL, 6000 IU/mL, 10000 IU/mL)
MODE OF ACTION:
Recombinant human erythropoietin; stimulates erythropoiesis via division and differentiation of progenitor cells in bone marrow.
INDICATIONS
Indicated in adult and paediatric patients for the:
• Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
• Treatment of anemia due to zidovudine in patients with HIV-infection.
• Treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
• Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
DOSAGE
In patients with CKD
Adults: Initial dose of 50 to 100 Units/kg 3 times weekly
Pediatric: 50 Units/kg 3 times weekly
Individualize maintenance dose. Intravenous route recommended for patients on hemodialysis.
STORAGE
2ᵒC to 8ᵒC, should not be freeze
DISCLAIMER
This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.